Clinical and pathologic risk factors of tumor recurrence in patients with node-negative early breast cancer after mastectomy

Journal of Surgical Oncology

Volumn 108, Issue 6, 2013, Pages 352-357

  Lin, Po Han ^a,b,c   Yeh, Ming Hsin ^b   Liu, Liang Chih ^b   Chen, Chih Jung ^b   Tsui, Yu Chu ^b   Su, Chen Hsien ^b   Wang, Hwei Chung ^b   Liang, Ji An ^b   Chang, Hui Wen ^b   Wu, Hsiao Su ^b   Yeh, Su Peng ^b,d   Li, Long Yuan ^a   Chiu, Chang Fang ^b,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

breast cancer; grade; lymphovascular invasion; node negative; radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RADIOTHERAPY; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; NODE NEGATIVE BREAST CANCER; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK FACTOR; TUMOR RECURRENCE;

BREAST CANCER; GRADE; LYMPHOVASCULAR INVASION; NODE-NEGATIVE; RADIOTHERAPY;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MASTECTOMY, MODIFIED RADICAL; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886773504     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23403     Document Type: Article

References (23)

1. Ferlay J, Shin HR, Bray F, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008; Int J Cancer 2010; 127: 2893-2917.
2. Romond EH, Jeong JH, Rastogi P, et al.: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 3792-3799.
3. Mackey JR, Martin M, Pienkowski T, et al.: Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013; 14: 72-80.
4. Janicke F, Prechtl A, Thomssen C, et al.: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-920.
5. Viale G, Regan MM, Maiorano E, et al.: Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 2008; 26: 1404-1410.
6. Joensuu H, Pylkkanen L, Toikkanen S:, Late mortality from pT1N0M0 breast carcinoma. Cancer 1999; 85: 2183-2189.
7. Livi L, Meattini I, Saieva C, et al.: Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer 2012; 118: 3236-3243.
8. Colleoni M, Rotmensz N, Maisonneuve P, et al.: Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 2007; 18: 1632-1640.
9. Schmidt M, Victor A, Bratzel D, et al.: Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-Comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 2009; 20: 258-264.
10. Karlsson P, Cole BF, Chua BH, et al.: Patterns and risk factors for locoregional failures after mastectomy for breast cancer: An International Breast Cancer Study Group report. Ann Oncol 2012; 23: 2852-2858.
11. Goldhirsch A, Wood WC, Coates AS, et al.: Strategies for subtypes-Dealing with the diversity of breast cancer: Highlights of the St. Gallen InternationalExpert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
12. Lee AH, Pinder SE, Macmillan RD, et al.: Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 2006; 42: 357-362.
13. Matsunuma R, Oguchi M, Fujikane T, et al.: Influence of lymphatic invasion on locoregional recurrence following mastectomy: Indication for postmastectomy radiotherapy for breast cancer patients with one to three positive nodes. Int J Radiat Oncol Biol Phys 2012; 83: 845-852.
14. Sotiriou C, Wirapati P, Loi S, et al.: Gene expression profiling in breast cancer: Understanding the molecular basis of histological grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272.
15. Rakha EA, Reis-Filho JS, Baehner F, et al.: Breast cancer prognostic classification in the molecular era: The role of histological grade. Breast Cancer Res 2010; 12: 207.
16. Lanigan F, McKiernan E, Brennan DJ, et al.: Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 2009; 124: 2088-2097.
17. Clarke M, Collins R, Darby S, et al.: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 366: 2087-2106.
18. Aebi S, Davidson T, Gruber G, Cardoso F:, Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22: vi12-vi24.
19. Duraker N, Demir D, Bati B, et al.: Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis. Jpn J Clin Oncol 2012; 42: 601-608.
20. Abdulkarim BS, Cuartero J, Hanson J, et al.: Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011; 29: 2852-2858.
21. Westenend PJ, Meurs CJ, Damhuis RA:, Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J Clin Pathol 2005; 58: 196-201.
22. Gamucci T, Vaccaro A, Ciancola F, et al.: Recurrence risk in small, node-negative, early breast cancer: Multicenter retrospective analysis. J Cancer Res Clin Oncol 2013; 139: 853-860.
23. Viale G, Giobbie-Hurder A, Gusterson BA, et al.: Adverse prognostic value of peritumoral vascular invasion: Is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol 2010; 21: 245-254.